Stock DNA
Pharmaceuticals & Biotechnology
JPY 468,311 Million (Mid Cap)
11.00
NA
0.00%
-0.35
8.87%
1.16
Revenue and Profits:
Net Sales:
592,872 Million
(Quarterly Results - Jun 2025)
Net Profit:
3,783 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.19%
0%
1.19%
6 Months
15.6%
0%
15.6%
1 Year
31.04%
0%
31.04%
2 Years
24.73%
0%
24.73%
3 Years
70.03%
0%
70.03%
4 Years
85.3%
0%
85.3%
5 Years
57.48%
0%
57.48%
Suzuken Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.63%
EBIT Growth (5y)
2.67%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.35
Sales to Capital Employed (avg)
5.73
Tax Ratio
31.39%
Dividend Payout Ratio
22.00%
Pledged Shares
0
Institutional Holding
0.39%
ROCE (avg)
11.93%
ROE (avg)
5.93%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.01
EV to EBIT
7.21
EV to EBITDA
5.45
EV to Capital Employed
1.01
EV to Sales
0.11
PEG Ratio
0.51
Dividend Yield
NA
ROCE (Latest)
13.97%
ROE (Latest)
9.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2018
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
592,872.00
582,196.00
1.83%
Operating Profit (PBDIT) excl Other Income
8,510.00
8,138.00
4.57%
Interest
10.00
9.00
11.11%
Exceptional Items
-14.00
-153.00
90.85%
Consolidate Net Profit
3,783.00
4,960.00
-23.73%
Operating Profit Margin (Excl OI)
9.40%
9.10%
0.03%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 1.83% vs 1.49% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -23.73% vs 48.73% in Jun 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
2,399,952.00
2,386,493.00
0.56%
Operating Profit (PBDIT) excl Other Income
49,189.00
43,620.00
12.77%
Interest
41.00
43.00
-4.65%
Exceptional Items
-2,306.00
-2,391.00
3.55%
Consolidate Net Profit
34,503.00
29,000.00
18.98%
Operating Profit Margin (Excl OI)
15.50%
14.60%
0.09%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 0.56% vs 3.10% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 18.98% vs 42.72% in Mar 2024
About Suzuken Co., Ltd. 
Suzuken Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






